Cargando…

Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression

BACKGROUND: Among women, breast cancer (BC) is the leading cancer and the most common cause of cancer-related death between 30 and 69 years. Although lifestyle and diet are considered to have a role in global BC incidence pattern, the specific influence of dyslipidemia in BC onset and progression is...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues dos Santos, Catarina, Fonseca, Isabel, Dias, Sérgio, Mendes de Almeida, JC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942620/
https://www.ncbi.nlm.nih.gov/pubmed/24571647
http://dx.doi.org/10.1186/1471-2407-14-132
_version_ 1782479101257318400
author Rodrigues dos Santos, Catarina
Fonseca, Isabel
Dias, Sérgio
Mendes de Almeida, JC
author_facet Rodrigues dos Santos, Catarina
Fonseca, Isabel
Dias, Sérgio
Mendes de Almeida, JC
author_sort Rodrigues dos Santos, Catarina
collection PubMed
description BACKGROUND: Among women, breast cancer (BC) is the leading cancer and the most common cause of cancer-related death between 30 and 69 years. Although lifestyle and diet are considered to have a role in global BC incidence pattern, the specific influence of dyslipidemia in BC onset and progression is not yet completely understood. METHODS: Fasting lipid profile (total cholesterol, LDL-C, HDL-C, and triglycerides) was prospectively assessed in 244 women with BC who were enrolled according to pre-set inclusion criteria: diagnosis of non-hereditary invasive ductal carcinoma; selection for surgery as first treatment, and no history of treatment with lipid-lowering or anti-diabetic drugs in the previous year. Pathological and clinical follow-up data were recorded for further inclusion in the statistical analysis. RESULTS: Univariate associations show that BC patients with higher levels of LDL-C at diagnosis have tumors that are larger, with higher differentiation grade, higher proliferative rate (assessed by Ki67 immunostaining), are more frequently Her2-neu positive and are diagnosed in more advanced stages. Cox regression model for disease-free survival (DFS), adjusted to tumor T and N stages of TNM classification, and immunohistochemical subtypes, revealed that high LDL-C at diagnosis is associated with poor DFS. At 25 months of follow up, DFS is 12% higher in BC patients within the third LDL-C tertile compared to those in the first tertile. CONCLUSIONS: This is a prospective study where LDL-C levels, at diagnosis, emerge as a prognostic factor; and this parameter can be useful in the identification and follow-up of high-risk groups. Our results further support a possible role for systemic cholesterol in BC progression and show that cholesterol metabolism may be an important therapeutic target in BC patients.
format Online
Article
Text
id pubmed-3942620
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39426202014-03-06 Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression Rodrigues dos Santos, Catarina Fonseca, Isabel Dias, Sérgio Mendes de Almeida, JC BMC Cancer Research Article BACKGROUND: Among women, breast cancer (BC) is the leading cancer and the most common cause of cancer-related death between 30 and 69 years. Although lifestyle and diet are considered to have a role in global BC incidence pattern, the specific influence of dyslipidemia in BC onset and progression is not yet completely understood. METHODS: Fasting lipid profile (total cholesterol, LDL-C, HDL-C, and triglycerides) was prospectively assessed in 244 women with BC who were enrolled according to pre-set inclusion criteria: diagnosis of non-hereditary invasive ductal carcinoma; selection for surgery as first treatment, and no history of treatment with lipid-lowering or anti-diabetic drugs in the previous year. Pathological and clinical follow-up data were recorded for further inclusion in the statistical analysis. RESULTS: Univariate associations show that BC patients with higher levels of LDL-C at diagnosis have tumors that are larger, with higher differentiation grade, higher proliferative rate (assessed by Ki67 immunostaining), are more frequently Her2-neu positive and are diagnosed in more advanced stages. Cox regression model for disease-free survival (DFS), adjusted to tumor T and N stages of TNM classification, and immunohistochemical subtypes, revealed that high LDL-C at diagnosis is associated with poor DFS. At 25 months of follow up, DFS is 12% higher in BC patients within the third LDL-C tertile compared to those in the first tertile. CONCLUSIONS: This is a prospective study where LDL-C levels, at diagnosis, emerge as a prognostic factor; and this parameter can be useful in the identification and follow-up of high-risk groups. Our results further support a possible role for systemic cholesterol in BC progression and show that cholesterol metabolism may be an important therapeutic target in BC patients. BioMed Central 2014-02-26 /pmc/articles/PMC3942620/ /pubmed/24571647 http://dx.doi.org/10.1186/1471-2407-14-132 Text en Copyright © 2014 Rodrigues dos Santos et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rodrigues dos Santos, Catarina
Fonseca, Isabel
Dias, Sérgio
Mendes de Almeida, JC
Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title_full Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title_fullStr Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title_full_unstemmed Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title_short Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression
title_sort plasma level of ldl-cholesterol at diagnosis is a predictor factor of breast tumor progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942620/
https://www.ncbi.nlm.nih.gov/pubmed/24571647
http://dx.doi.org/10.1186/1471-2407-14-132
work_keys_str_mv AT rodriguesdossantoscatarina plasmalevelofldlcholesterolatdiagnosisisapredictorfactorofbreasttumorprogression
AT fonsecaisabel plasmalevelofldlcholesterolatdiagnosisisapredictorfactorofbreasttumorprogression
AT diassergio plasmalevelofldlcholesterolatdiagnosisisapredictorfactorofbreasttumorprogression
AT mendesdealmeidajc plasmalevelofldlcholesterolatdiagnosisisapredictorfactorofbreasttumorprogression